SCLEROSTIN BINDING AGENT
PROBLEM TO BE SOLVED: To provide a pharmaceutical composition that contains an antibody capable of binding to Sclerostin as a protein.SOLUTION: A pharmaceutical composition contains an antibody having a light chain variable domain consisting of an amino acid sequence shown by SEQ ID No. 376 and a he...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | GRAHAM KEVIN LATHAM JOHN POPPLEWELL ANDY SHEN WENYAN ROBINSON MARTY KIM HOFFMANN KELLY SUE HENRY ALISTAIR JAMES LU HSIENG SEN PASZTY CHRISTOPHER WINKLER DAVID WINTERS AARON GEORGE LAWSON ALASTAIR |
| description | PROBLEM TO BE SOLVED: To provide a pharmaceutical composition that contains an antibody capable of binding to Sclerostin as a protein.SOLUTION: A pharmaceutical composition contains an antibody having a light chain variable domain consisting of an amino acid sequence shown by SEQ ID No. 376 and a heavy chain variable domain consisting of an amino acid sequence shown by SEQ ID No. 378. The antibody binds to Sclerostin as SEQ ID No. 1 with a binding affinity (Kd) lower than, or equal to, 1×10M. or bonds to the sucre loss Canis familiaris var. domesticus of SEQ ID NO 1 by binding affinity (Kd) equal to 1×10M. The pharmaceutical composition can be used for treatment or prevention of a pathologic disorder developed through the medium of Sclerostin or associated with a rise in the Sclerostin level. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JP2013249303A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JP2013249303A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JP2013249303A3</originalsourceid><addsrcrecordid>eNrjZJAIdvZxDfIPDvH0U3Dy9HPx9HNXcHR39QvhYWBNS8wpTuWF0twMSm6uIc4euqkF-fGpxQWJyal5qSXxXgFGBobGRiaWxgbGjsZEKQIAMbcgGQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>SCLEROSTIN BINDING AGENT</title><source>esp@cenet</source><creator>GRAHAM KEVIN ; LATHAM JOHN ; POPPLEWELL ANDY ; SHEN WENYAN ; ROBINSON MARTY KIM ; HOFFMANN KELLY SUE ; HENRY ALISTAIR JAMES ; LU HSIENG SEN ; PASZTY CHRISTOPHER ; WINKLER DAVID ; WINTERS AARON GEORGE ; LAWSON ALASTAIR</creator><creatorcontrib>GRAHAM KEVIN ; LATHAM JOHN ; POPPLEWELL ANDY ; SHEN WENYAN ; ROBINSON MARTY KIM ; HOFFMANN KELLY SUE ; HENRY ALISTAIR JAMES ; LU HSIENG SEN ; PASZTY CHRISTOPHER ; WINKLER DAVID ; WINTERS AARON GEORGE ; LAWSON ALASTAIR</creatorcontrib><description>PROBLEM TO BE SOLVED: To provide a pharmaceutical composition that contains an antibody capable of binding to Sclerostin as a protein.SOLUTION: A pharmaceutical composition contains an antibody having a light chain variable domain consisting of an amino acid sequence shown by SEQ ID No. 376 and a heavy chain variable domain consisting of an amino acid sequence shown by SEQ ID No. 378. The antibody binds to Sclerostin as SEQ ID No. 1 with a binding affinity (Kd) lower than, or equal to, 1×10M. or bonds to the sucre loss Canis familiaris var. domesticus of SEQ ID NO 1 by binding affinity (Kd) equal to 1×10M. The pharmaceutical composition can be used for treatment or prevention of a pathologic disorder developed through the medium of Sclerostin or associated with a rise in the Sclerostin level.</description><language>eng</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2013</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20131212&DB=EPODOC&CC=JP&NR=2013249303A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76516</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20131212&DB=EPODOC&CC=JP&NR=2013249303A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>GRAHAM KEVIN</creatorcontrib><creatorcontrib>LATHAM JOHN</creatorcontrib><creatorcontrib>POPPLEWELL ANDY</creatorcontrib><creatorcontrib>SHEN WENYAN</creatorcontrib><creatorcontrib>ROBINSON MARTY KIM</creatorcontrib><creatorcontrib>HOFFMANN KELLY SUE</creatorcontrib><creatorcontrib>HENRY ALISTAIR JAMES</creatorcontrib><creatorcontrib>LU HSIENG SEN</creatorcontrib><creatorcontrib>PASZTY CHRISTOPHER</creatorcontrib><creatorcontrib>WINKLER DAVID</creatorcontrib><creatorcontrib>WINTERS AARON GEORGE</creatorcontrib><creatorcontrib>LAWSON ALASTAIR</creatorcontrib><title>SCLEROSTIN BINDING AGENT</title><description>PROBLEM TO BE SOLVED: To provide a pharmaceutical composition that contains an antibody capable of binding to Sclerostin as a protein.SOLUTION: A pharmaceutical composition contains an antibody having a light chain variable domain consisting of an amino acid sequence shown by SEQ ID No. 376 and a heavy chain variable domain consisting of an amino acid sequence shown by SEQ ID No. 378. The antibody binds to Sclerostin as SEQ ID No. 1 with a binding affinity (Kd) lower than, or equal to, 1×10M. or bonds to the sucre loss Canis familiaris var. domesticus of SEQ ID NO 1 by binding affinity (Kd) equal to 1×10M. The pharmaceutical composition can be used for treatment or prevention of a pathologic disorder developed through the medium of Sclerostin or associated with a rise in the Sclerostin level.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2013</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJAIdvZxDfIPDvH0U3Dy9HPx9HNXcHR39QvhYWBNS8wpTuWF0twMSm6uIc4euqkF-fGpxQWJyal5qSXxXgFGBobGRiaWxgbGjsZEKQIAMbcgGQ</recordid><startdate>20131212</startdate><enddate>20131212</enddate><creator>GRAHAM KEVIN</creator><creator>LATHAM JOHN</creator><creator>POPPLEWELL ANDY</creator><creator>SHEN WENYAN</creator><creator>ROBINSON MARTY KIM</creator><creator>HOFFMANN KELLY SUE</creator><creator>HENRY ALISTAIR JAMES</creator><creator>LU HSIENG SEN</creator><creator>PASZTY CHRISTOPHER</creator><creator>WINKLER DAVID</creator><creator>WINTERS AARON GEORGE</creator><creator>LAWSON ALASTAIR</creator><scope>EVB</scope></search><sort><creationdate>20131212</creationdate><title>SCLEROSTIN BINDING AGENT</title><author>GRAHAM KEVIN ; LATHAM JOHN ; POPPLEWELL ANDY ; SHEN WENYAN ; ROBINSON MARTY KIM ; HOFFMANN KELLY SUE ; HENRY ALISTAIR JAMES ; LU HSIENG SEN ; PASZTY CHRISTOPHER ; WINKLER DAVID ; WINTERS AARON GEORGE ; LAWSON ALASTAIR</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JP2013249303A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2013</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>GRAHAM KEVIN</creatorcontrib><creatorcontrib>LATHAM JOHN</creatorcontrib><creatorcontrib>POPPLEWELL ANDY</creatorcontrib><creatorcontrib>SHEN WENYAN</creatorcontrib><creatorcontrib>ROBINSON MARTY KIM</creatorcontrib><creatorcontrib>HOFFMANN KELLY SUE</creatorcontrib><creatorcontrib>HENRY ALISTAIR JAMES</creatorcontrib><creatorcontrib>LU HSIENG SEN</creatorcontrib><creatorcontrib>PASZTY CHRISTOPHER</creatorcontrib><creatorcontrib>WINKLER DAVID</creatorcontrib><creatorcontrib>WINTERS AARON GEORGE</creatorcontrib><creatorcontrib>LAWSON ALASTAIR</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>GRAHAM KEVIN</au><au>LATHAM JOHN</au><au>POPPLEWELL ANDY</au><au>SHEN WENYAN</au><au>ROBINSON MARTY KIM</au><au>HOFFMANN KELLY SUE</au><au>HENRY ALISTAIR JAMES</au><au>LU HSIENG SEN</au><au>PASZTY CHRISTOPHER</au><au>WINKLER DAVID</au><au>WINTERS AARON GEORGE</au><au>LAWSON ALASTAIR</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>SCLEROSTIN BINDING AGENT</title><date>2013-12-12</date><risdate>2013</risdate><abstract>PROBLEM TO BE SOLVED: To provide a pharmaceutical composition that contains an antibody capable of binding to Sclerostin as a protein.SOLUTION: A pharmaceutical composition contains an antibody having a light chain variable domain consisting of an amino acid sequence shown by SEQ ID No. 376 and a heavy chain variable domain consisting of an amino acid sequence shown by SEQ ID No. 378. The antibody binds to Sclerostin as SEQ ID No. 1 with a binding affinity (Kd) lower than, or equal to, 1×10M. or bonds to the sucre loss Canis familiaris var. domesticus of SEQ ID NO 1 by binding affinity (Kd) equal to 1×10M. The pharmaceutical composition can be used for treatment or prevention of a pathologic disorder developed through the medium of Sclerostin or associated with a rise in the Sclerostin level.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_JP2013249303A |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | SCLEROSTIN BINDING AGENT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T20%3A39%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=GRAHAM%20KEVIN&rft.date=2013-12-12&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJP2013249303A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |